Last checked at 28 Apr 2016 11:07
Transaction with Affiliate Company - Purchase of Samsung Biologics Shares
On 28th April 2016, the board of directors of Samsung Electronics Co., Ltd. authorized the purchase of
shares of its affiliate, Samsung Biologics Co., Ltd., from Quintiles Asia, Inc.
Details of Purchase
1. Items of Transaction:
276,400 common shares of Samsung Biologics from Quintiles Asia, Inc.
- Transaction value: KRW 14,275 million (Total investment volume: KRW 559,940 million)
2. Purpose of transaction
Required pro rata purchase of Quintiles Asia's shares of Samsung Biologics Co., Ltd., pursuant to Quintiles Asia's exercise of its put option.
3. Number of Independent Directors Present at the BOD Meeting: 5 (100%)
4. Attendance of Audit Committee Members at the BOD Meeting: Y
※ Note: This disclosure is in accordance with the Korean Fair Trade Act Article 11-2 (Resolution of the Board of Directors and its Publication on Large-Scale Intra-Group Transaction) and Samsung Electronics the Article of Incorporation Article 40-1 which states any company belonging to a Corporate Group falling under the Presidential Decree with intend to channeling or trading funds, offering or trading securities, offering or trading assets, and/or offering or trading good and services that exceeds KRW 5 billion shall publish such intention in advance following a resolution of the Board of directors. This transaction is expected to be completed during May 2016 and its contents may change in the process of acquiring the shares.